Investigation of Setmelanotide, an MC4R Agonist, for Obesity in Individuals with Smith-Magenis Syndrome

Overview

Journal Obes Res Clin Pract

Publisher Elsevier

Specialty Endocrinology

Date 2024 Jul 10

PMID 38987029

Authors

Julia Lazareva

Stephanie R Sisley

Sheila M Brady

Ann C M Smith

Sarah H Elsea

Jeremy J Pomeroy

Christian L Roth

Jennifer E Sprague

Martin Wabitsch

Jill Garrison

Jack A Yanovski

Affiliations

Soon will be listed here.

Abstract

Background: Smith Magenis Syndrome (SMS) is a rare genetic disorder caused by RAI1 haploinsufficiency. Obesity in people with SMS is believed partially due to dysfunction of the proximal melanocortin 4 receptor (MC4R) pathway. We therefore studied effects of treatment with the MC4R agonist setmelanotide on obesity and hunger, as well as metabolic, cardiac and safety, in individuals with SMS.

Methods: People with SMS received once-daily setmelanotide injections, with the dose titrated bi-weekly to a maximum of 3 mg over ∼1 month; and a full-dose treatment duration of 3mo. The primary outcome was percent change in body weight. Secondary outcomes included hunger, waist circumference, body composition, and safety.

Results: 12 individuals, ages 11-39 y, enrolled and 10 completed the full-dose treatment phase. Mean percent change in body weight at end-treatment was - 0.28 % [(95 % CI, -2.1 % to 1.5 %; n = 12; P = 0.66]. Participants experienced a significant decrease in total cholesterol associated with a significant decrease in HDL-cholesterol and a trend for lower LDL-cholesterol. Self-reported hunger was reduced at end-treatment (p = 0.011). All participants reported adverse events (AEs), most commonly injection-site reactions and skin hyperpigmentation. No AEs led to withdrawal or death.

Conclusions: In this trial, setmelanotide did not significantly reduce body weight in participants with SMS. Participants reported significant differences in hunger, but such self-reports are difficult to interpret without a placebo-treated group. The changes in lipid profiles require further investigation. Results of this study do not suggest that dysfunction of the proximal MC4R pathway is the main etiology for obesity in people with SMS.

References

Clement K, Biebermann H, Farooqi I, van der Ploeg L, Wolters B, Poitou C . MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018; 24(5):551-555. DOI: 10.1038/s41591-018-0015-9. View

Boot E, Linders C, Tromp S, van den Boogaard M, Van Eeghen A . Possible underreporting of pathogenic variants in RAI1 causing Smith-Magenis syndrome. Am J Med Genet A. 2021; 185(10):3167-3169. PMC: 8519085. DOI: 10.1002/ajmg.a.62380. View

Rinaldi B, Villa R, Sironi A, Garavelli L, Finelli P, Bedeschi M . Smith-Magenis Syndrome-Clinical Review, Biological Background and Related Disorders. Genes (Basel). 2022; 13(2). PMC: 8872351. DOI: 10.3390/genes13020335. View

Kuhnen P, Clement K, Wiegand S, Blankenstein O, Gottesdiener K, Martini L . Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist. N Engl J Med. 2016; 375(3):240-6. DOI: 10.1056/NEJMoa1512693. View

Han J, Liu Q, Jones M, Levinn R, Menzie C, Jefferson-George K . Brain-derived neurotrophic factor and obesity in the WAGR syndrome. N Engl J Med. 2008; 359(9):918-27. PMC: 2553704. DOI: 10.1056/NEJMoa0801119. View

Beckers S, Zegers D, Van Gaal L, Van Hul W . The role of the leptin-melanocortin signalling pathway in the control of food intake. Crit Rev Eukaryot Gene Expr. 2009; 19(4):267-87. DOI: 10.1615/critreveukargeneexpr.v19.i4.20. View

Xu B, Goulding E, Zang K, Cepoi D, Cone R, Jones K . Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci. 2003; 6(7):736-42. PMC: 2710100. DOI: 10.1038/nn1073. View

Farooqi I, Drop S, Clements A, Keogh J, Biernacka J, Lowenbein S . Heterozygosity for a POMC-null mutation and increased obesity risk in humans. Diabetes. 2006; 55(9):2549-53. DOI: 10.2337/db06-0214. View

Slager R, Newton T, Vlangos C, Finucane B, Elsea S . Mutations in RAI1 associated with Smith-Magenis syndrome. Nat Genet. 2003; 33(4):466-8. DOI: 10.1038/ng1126. View

10.

Elatrash C, Shi J, Wilson T, Elsea S, Sisley S . Blind to the perils of pursuing food: Behaviors of individuals with Smith-Magenis Syndrome. Genet Med Open. 2024; 2. PMC: 11309085. DOI: 10.1016/j.gimo.2024.101857. View

11.

Wei R, Ogden C, Parsons V, Freedman D, Hales C . A method for calculating BMI z-scores and percentiles above the 95 percentile of the CDC growth charts. Ann Hum Biol. 2020; 47(6):514-521. PMC: 11232929. DOI: 10.1080/03014460.2020.1808065. View

12.

Burns B, Schmidt K, Williams S, Kim S, Girirajan S, Elsea S . Rai1 haploinsufficiency causes reduced Bdnf expression resulting in hyperphagia, obesity and altered fat distribution in mice and humans with no evidence of metabolic syndrome. Hum Mol Genet. 2010; 19(20):4026-42. PMC: 7714048. DOI: 10.1093/hmg/ddq317. View

13.

Haws R, Brady S, Davis E, Fletty K, Yuan G, Gordon G . Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. Diabetes Obes Metab. 2020; 22(11):2133-2140. PMC: 7689750. DOI: 10.1111/dom.14133. View

14.

Haqq A, Chung W, Dollfus H, Haws R, Martos-Moreno G, Poitou C . Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022; 10(12):859-868. PMC: 9847480. DOI: 10.1016/S2213-8587(22)00277-7. View

15.

Zhang X, Ha S, Lau H, Yu J . Excess body weight: Novel insights into its roles in obesity comorbidities. Semin Cancer Biol. 2023; 92:16-27. DOI: 10.1016/j.semcancer.2023.03.008. View

16.

Gray J, Yeo G, Cox J, Morton J, Adlam A, Keogh J . Hyperphagia, severe obesity, impaired cognitive function, and hyperactivity associated with functional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene. Diabetes. 2006; 55(12):3366-71. PMC: 2413291. DOI: 10.2337/db06-0550. View